Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.82 USD | -2.74% | -3.09% | -7.87% |
Financials (USD)
Sales 2024 * | 99.02M | Sales 2025 * | 181M | Capitalization | 485M |
---|---|---|---|---|---|
Net income 2024 * | -126M | Net income 2025 * | -62M | EV / Sales 2024 * | 4.34 x |
Net cash position 2024 * | 55.62M | Net cash position 2025 * | 277M | EV / Sales 2025 * | 1.15 x |
P/E ratio 2024 * |
-3.85
x | P/E ratio 2025 * |
-8.28
x | Employees | 200 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.65% |
Latest transcript on UroGen Pharma Ltd.
1 day | -2.74% | ||
1 week | -3.09% | ||
Current month | -7.87% | ||
1 month | -17.05% | ||
3 months | -9.79% | ||
6 months | +22.19% | ||
Current year | -7.87% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 19-01-02 | |
Dong Kim
DFI | Director of Finance/CFO | 47 | 21-07-31 |
Jason Smith
CMP | Compliance Officer | 52 | 20-09-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arie Belldegrun
CHM | Chairman | 74 | 12-09-30 |
Cynthia Butitta
BRD | Director/Board Member | 70 | 17-09-30 |
Fred Cohen
BRD | Director/Board Member | 67 | 17-05-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +2.22% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 13.82 | -2.74% | 184,212 |
24-04-24 | 14.21 | -2.20% | 97,025 |
24-04-23 | 14.53 | +1.11% | 216,766 |
24-04-22 | 14.37 | +4.66% | 278,571 |
24-04-19 | 13.73 | -3.72% | 389,484 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.87% | 485M | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- URGN Stock